Cue Biopharma (CUE) EBITDA (2017 - 2026)

Cue Biopharma has disclosed EBITDA across 10 years of filings, most recently posting -$87.7 million for Q2 2026.

• In Q2 2026, EBITDA fell 915.58% year-over-year to -$87.7 million; the TTM figure through Jun 2026 stood at -$101.9 million (down 158.87% YoY), while the FY2025 annual figure was -$26.6 million, up 36.02% from the prior year.
• EBITDA came in at -$87.7 million for Q2 2026 at Cue Biopharma, down from $2.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.0 million in Q4 2025 to a low of -$87.7 million in Q2 2026.
• Average EBITDA over 5 years is -$15.4 million, with a median of -$12.3 million recorded in 2025.
• Year-over-year, EBITDA soared 120.53% in 2025 and tumbled 915.58% in 2026.
• Over 5 years, EBITDA stood at -$14.9 million in 2022, then increased by 6.96% to -$13.8 million in 2023, then jumped by 30.36% to -$9.6 million in 2024, then soared by 120.53% to $2.0 million in 2025, then plunged by 4533.52% to -$87.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$87.7 million in Q2 2026, $2.0 million in Q4 2025, and -$7.6 million in Q3 2025.